Drug name
Last update: Oct 2026ACC017
Developer(s)
Drug information
Not provided
ACC017 (investigational)
Not applicable (investigational; no brand name assigned)
Small molecule
INSTI (Integrase strand transfer inhibitor)
ACC017 is an investigational integrase strand transfer inhibitor (molecular formula C22H21F2N3O5; CAS 2765212-92-6) discovered and developed by Jiangsu Aidea Pharmaceutical Group (China), with preclinical work at the Kunming Institute of Zoology, Chinese Academy of Sciences. In vitro, it showed potent activity against HIV-1 IIIB (EC50 0.59 nM), clinical isolates (EC50 0.11-1.78 nM) and a panel of drug-resistant strains (EC50 0.34-9.12 nM); resistance selection yielded D232N and R263K without G140 or Q148 pathway mutations. ACC017 is developed as a once-daily oral tablet: a placebo-controlled phase 1b/2a monotherapy study (NCT06719310) showed potent antiviral activity and PK supporting once-daily dosing. A phase 3 trial versus dolutegravir in treatment-naive adults (about 660 participants, 48 weeks) started in China in October 2025. No long-acting formulation has been reported.
ACC017 is an investigational INSTI being developed as a once-daily oral tablet, now in phase 3. A three-drug fixed-dose combination (ADC118: ACC017/FTC/TAF) received NMPA clinical trial approval on 28 October 2025.
Not officially reported
Therapeutic area(s)
- HIV
- Treatment
Administration route
Oral
Associated long-acting platforms
Oral solid form
Use of drug
- Self-administered
- Daily
Dosage
Oral tablets; 5 mg, 40 mg and 80 mg once daily studied in phase 1b/2a (NCT06719310). Phase 3 dose not disclosed.
80 mg once daily (highest dose in phase 1b/2a)
Not established. Phase 1b/2a (NCT06719310): ACC017 5, 40 or 80 mg once daily monotherapy for 10 days, then with FTC/TAF 200/25 mg once daily for 18 days. Phase 3 (CTR20253999): ACC017-based regimen versus dolutegravir, 48 weeks (dose not disclosed).
Not provided
Not provided
Related entries
Not provided
Additional information
Developer(s)
Aidea Pharma
Jiangsu Aidea Pharmaceutical is a Shanghai-listed Chinese pharmaceutical company based in Yangzhou, Jiangsu, whose pipeline includes several anti-HIV medicines.
Drug structure
Scale-up and manufacturing prospects
Not provided
Not provided
Not provided
Not provided
Excipients & delivery device(s)
Not provided
Not provided
Not provided
Not provided
Safety, Efficacy and Evidence Summary
Not provided
Not provided
Not provided
Not provided
There are either no relevant patents or these were not yet submitted to LAPaL